CD8A and neoplasm: Overall, vaccine strategies aiming at inducing a pool of tumor-specific CD8+ T cells as well to reactivate pre-existing anergic tumor-specific CD8+ T cells, would be of great benefit for the development of new, safer, and more effective anticancer strategies [7].